Month: February 2020

CNOVA N.V.Résultats financiers 2019AMSTERDAM, le 18 février 2019, 7h45 CET — Cnova N.V. (Euronext Paris  : CNV ; ISIN  : NL0010949392) (« Cnova » ou la « Société ») annonce aujourd’hui les résultats financiers non audités de l’exercice clos le 31 décembre 20191.GMV : 3,9 milliards d’euros (+9,1 % de croissance organique2)Contribution marketplace : +3,9 pts portés par une hausse de sa quote-part (38,1 % ; +3,7 pts)3Contribution des services B2C : +3,4 pts portés par l’expansion rapide du voyage (GMV x10)Quote-part mobile : 49,5 % du GMV (+5,5 pts)Quote-part CDAV : 35,8 % du GMV (+1,7 pts)Expansion de la plateforme internationale : +85 % au T4 2019 vs T4 2018EBITDA4 : 79 millions d’euros (+31 M€ vs. 2018)EBITDA avant IFRS16 : 51 M€ (+25 M€) en ligne avec les prévisionsAmélioration de la marge brute : 17,8 % (+2,3 pts) tirés par la marketplace...

CGG Completes Exit from Land Data AcquisitionParis, February 18, 2020CGG announced today that it has completed the wind-down and exit from its land seismic data acquisition business after completing its last land seismic acquisition contract in Tunisia. Following on from the company’s recently announced exits from seabed and marine data acquisition, this milestone marks the successful completion of CGG’s strategy to exit the seismic data acquisition business. To date, CGG still retains a minority shareholding in the ARGAS company operating in the Middle East.Sophie Zurquiyah, CEO of CGG, said: “The exit from our seismic data acquisition business, one of CGG’s long-standing historic areas of expertise, marks the end of an era, and also the start of an exciting new chapter in our history. This is a key milestone in our CGG 2021 strategic...

CGG Arrête Définitivement son Activitéd’Acquisition de Données TerrestresParis, France – le 18 février 2020CGG annonce ce jour avoir finalisé l’arrêt définitif de son activité d’acquisition de données sismiques terrestres après la fin du dernier contrat d’acquisition sismique terrestre en Tunisie. Cette annonce, qui intervient après la sortie récente des métiers d’acquisition marine et fond de mer, confirme la mise en œuvre réussie de la stratégie de CGG de quitter le secteur de l’acquisition de données sismiques.A ce jour, CGG détient toujours une participation minoritaire dans la société ARGAS qui opère au Moyen-Orient.Sophie Zurquiyah, Directeur Général de CGG, a déclaré: « Notre sortie des métiers d’acquisition de données sismiques, l’un des domaines d’expertise historiques de CGG, marque la fin d’une...

Omsætningen blev 314 mio. kr., og resultatet nåede 89 mio. kr. inklusive indtægter fra salget af Jobbsafari i SverigeStrukturen er tilpasset markedet, og det nye år er startet pænt, og Jobindex forventer en lille vækst i markedet i 2020Gode resultater trods opbremsning“Det er gået godt for koncernen i 2019 trods opbremsning og usikkerhed, blandt andet som følge af Brexit og risiko for handelskrig,” siger Kaare Danielsen. “Vi har fået et fint resultat, hvor vi har indfriet forventningerne. Samtidigt har vi indrettet os på fremtiden: Udover at afhænde Jobbsafari i Sverige har vi slået salgsafdelingerne for StepStone og Jobindex sammen, hvilket giver god synergi. Computerworld og it-jobbank er også begyndt at arbejde tættere sammen og har præsteret flotte resultater i 2019,” siger Kaare Danielsen. Forventer svagt...

Revenue contributions from Cresemba®and Zevtera®increased 39% to CHF 114 millionOperating result improved by 29%Start of urothelial cancer study for derazantinib with immunotherapy combination and further expansion planned into gastric cancerPositive topline results reported from ceftobiprole phase 3 skin infection (ABSSSI) studyYear-end cash and investments of CHF 161 million and reduction innet operating cash consumptionIn 2020, revenue contributions from Cresemba and Zevtera, excluding deferred revenue, expected to grow 12% to 27% year-on-yearBasel, Switzerland, February 18, 2020 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today its financial results for the financial year ended December 31, 2019.David Veitch, Chief Executive Officer, said: “Basilea made significant progress in 2019. Revenue contributions from our two marketed...

Umsatzbeiträge aus Cresemba®und Zevtera®um 39 % auf CHF 114 Mio erhöhtBetriebsergebnis um 29 % verbessertStart einer Blasenkrebs-Studie mit Derazantinib in Kombination mit Immuntherapie; Ausweitung auf Magenkrebs geplantPositive Topline-Ergebnisse für Phase-3-Studie mit Ceftobiprol bei Hautinfektionen (ABSSSI)Zum Jahresende CHF 161 Mio. liquide Mittel und Finanzanlagen und Verringerung des Netto-Barmittelverbrauchs für die operative GeschäftstätigkeitFür 2020 Zuwachs der Umsatzbeiträge (ohne Verbuchung von unrealisiertem Ertrag) von Cresemba und Zevtera um 12 % bis 27 % im Jahresvergleich erwartetBasel, 18. Februar 2020 – Basilea Pharmaceutica AG (SIX: BSLN) gab heute ihre Finanzergebnisse für das Geschäftsjahr 2019 bekannt.Chief Executive Officer David Veitch sagte: „Basilea hat 2019 signifikante Fortschritte erzielt. Die Umsatzbeiträge...

18 February 2020, Limassol, CyprusIn reference to the Strategy Update released on November 7th last year, Seabird Exploration Plc announces the following:The Company has entered into a MUSD 16 three-year secured credit facility with Sparebanken 1 SMN.  The proceeds from the loan will be used to repay the SBX04 bond loan expiring in June, and to outfit the “Fulmar Explorer” for seismic operations. The outfitting project will commence in Q1 with an expected duration of 3 months. Marketing of the “Fulmar Explorer” will begin immediately.The Company has signed a 2-year, plus 2×1 year options, “pay as you work” flexible charter agreement with Uksnøy & Co AS for the 2007-built «Geo Barents». The vessel will be equipped for source, 2D and niche 3D work with expected availability ultimo March. The company will begin marketing the vessel...

New York, NY, February 18, 2020: OpenRisk Technologies Inc., the leading industry provider of a complementary suite of innovative business-centric products in Unstructured Data Management, Process Automation, Risk Management, and Knowledge Analytics & Insights, and Agelix Consulting LLC. today announced the formation of a new strategic partnership to offer seamless and holistic business solutions across several industries, leveraging OpenRisk products and combined business and technology expertise. The partnership advances OpenRisk in disrupting the digitization and rationalization of diverse set of complex unstructured data into actionable insights for holistic risk management and operational efficiencies. OpenRisk’s innovative platform combined with Agelix’s deep expertise in product development, implementation, and support strategies...

WISeKey drives innovations in IoT security with 23 strategic patents in the U.S.Geneva, Switzerland/New York, USA – 18 February – WISeKey International Holding Ltd. (“WISeKey” NASDAQ: WKEY; SIX Swiss Exchange: WIHN), cybersecurity delivering Integrated Security Platforms, today announced that it has registered a total of 23 new strategic patents in U.S. which are essential to the digital transformation applications that are fueling the growth in the IoT market (see list of U.S. patents here).With a rich portfolio of more than 46 patent families, covering over 100 fundamental individual patents, and another 22 patents under review, WISeKey continues to expand its technology footprint in various domains including the design of secure chips, near field communication (NFC), the development of security firmware and backend software, the secure...

Geneva, Switzerland and Boston, MA – February 18, 2019 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health today announced that CEO Ernest Loumaye will present an update on the Company and its pipeline at the SVB LEERINK  9th Annual Global Healthcare Conference taking place February 25-27th, 2020, in New York City. Mr. Loumaye’s presentation will take place on Wednesday, February 26, 2020 at 9:30 a.m. Eastern Time (ET) A live webcast of  the presentation will be available under “Events Calendar” in the investors section of ObsEva’s website at www.ObsEva.com About ObsEvaObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing...